Abstract: Background: Computer-aided drug design is still a state-of-the-art process in medicinal chemistry, and the main topics in this field have been extensively studied and well reviewed. These topics include compound databases, ligand-binding pocket prediction, protein-compound docking, virtual screening, target/off-target prediction, physical property prediction, molecular simulation and pharmacokinetics/pharmacodynamics (PK/PD) prediction. Message and Conclusion: However, there are also a number of secondary or miscellaneous topics that have been less well covered. For example, methods for synthesizing and predicting the synthetic accessibility (SA) of designed compounds are important in practical drug development, and hardware/software resources for performing the computations in computer-aided drug design are crucial. Cloud computing and general purpose graphics processing unit (GPGPU) computing have been used in virtual screening and molecular dynamics simulations. Not surprisingly, there is a growing demand for computer systems which combine these resources. In the present review, we summarize and discuss these various topics of drug design.
INTRODUCTION
We review miscellaneous topics in computer-aided drug design (CADD), including non-scientific, technical, old and forgotten topics, since there have been a number of good reviews published already on the major topics in CADD. Computer-aided drug design is an assemblage of various computational methods and resources. These include compound databases, molecular dynamics simulations, ligand-binding pocket predictions, protein-compound dockings, structure-based drug screenings, ligand-based drug screenings, similarity searches, de-novo drug design, property predictions like LogS (aqueous solubility) and LogP ow (water-octanol partitioning coefficient) prediction, target/off target predictions, and predictions of synthetic accessibility. Fig. (1) shows the relationship among these methods. They are based on the chemical compound structures, while the pharmacokinetics and pharmacodynamics studies are mainly based on the experimental data.
There have been many reviews reporting on compound databases, molecular dynamics simulation, ligand-binding pocket prediction, protein-compound docking, structure-based drug screening, ligand-based drug screening, similarity searches, and de-novo drug design. Thus, in the present review, we focus on a number of important but less-studied topics. We review the synthetic accessibility (SA) prediction SA is an important aspect of drug design, since in some cases computer-designed compounds cannot be synthesized. In addition, we briefly consider the correlation between the sales price of approved drugs and the SA values. drug design. However, the predicted reaction paths can be unrealistic in some cases, since steric effects (such as atom collisions and other inter-atomic interactions) are not taken into consideration in these approaches and the reaction databases include incorrect entries.
Fig. (4) shows one example of an SA prediction based on reaction data [7, 11, 12, 16] . The compound in question is decomposed into fragments by breaking the relatively unstable bonds. This process is repeated until these fragments reach the starting chemicals included in the database. The bond breaking is performed based on the reaction database. This decomposition process generates a number of reaction paths. Then the difficulty of each reaction is estimated and the total SA of the compound in question is calculated. There are several ways to estimate the SA. One method evaluates the depth of the shortest path among all the predicted paths, since the SA depends on the reaction steps from the starting materials to the final product [7] . Generally speaking, if the compound is synthesized within 5 steps, the synthesis is easy. The other method evaluates the SA by considering the number of possible reaction paths, the difficulty of each step in the predicted path, and LogP on which the difficulty of the purification process depends [7] . The difficulty of synthesis will be decreased if the number of possible reaction paths increases. The difficulties of the reactions are estimated by chemists a priori. LogP prediction is more precise than LogS prediction and the descriptor-based LogP prediction is fast enough for practical use.
These retro-synthesis approaches depend on the reaction database. Satoh et al. examined the 329 data entries of the ChemInform (ISIS-ChemInform MDL-Information systems Inc.) database [18] . They reported that 46% of the data contained some error. Namely, they found wrong numbers of reaction steps in 25% of the data, and wrong reactions in 21%, wrong reaction sites in 19%, wrong chemical structures in 15%, wrong reaction conditions in 9% and wrong yield constants in 5% of the data. Most of the errors were human input errors. The SA and reaction path prediction theory should be improved in the future, as same as the theory, the quality check of various databases should be important. 
SYNTHETIC ACCESSIBILITY PREDICTION WITHOUT A REACTION DATABASE
A quantitative SA prediction method was reported by Takaoka et al. (2003) [13] . This method had two important features. First, it is able to predict SA values based on only the chemical structure of the compound in question and thus does not require a reaction database. Second, the method has already been assessed in a study in which expert manual assessment was used to evaluate the SA (in the original paper, "synthetic easiness") of compounds in a teaching data set. The compounds in the teaching data set were described by molecular descriptors, and the weights of the descriptors were determined to reproduce the SA. This approach worked well, suggesting that SA is useful.
Of course, SA is not a well-defined concept but a fuzzy idea [14] . Many years ago, people thought that organic compounds could not be synthesized by humans but only by God. In the 19 th century, organic compounds were made from charcoal and organic polymers could not be synthesized. In the middle of the 20 th century, many reactions were developed based on oil. Thus, the SA values of compounds would have changed in each epoch along with the available organic chemistry.
The latest methods are based on a commercially available compound database and molecular descriptors. In these methods [13, 15] , reaction databases and retro-synthesis analyses are not necessary (see Fig. 5 ). Instead, SA is estimated from the probability of the existence of substructures of the compound calculated based on a compound library, the number of symmetry atoms, and the number of chiral centers in the compound. A steric effect, such as that of atomic collision, could be partially taken into consideration by the probability of the existence of substructures of the compound. It has recently become easier to access free compound databases, such as PUBChem [19] , ChEMBL [20] , ZINC [21, 22] , and LigandBOX [23, 24] , and many vendors have made the catalogs of their compounds (see Table 2 ). In general, the databases of compound structures are more reliable than the reaction databases. Table 2 shows trends in the number of compounds provided by some of the major compound vendors available on the LigandBOX database (URL http://ligandbox.protein.osaka-u.ac.jp/ligandbox// cgi-bin/index.cgi?LANG=en). As shown in this table, the total number of commercially available compounds (stocks) has not changed for several years. Every year, several hundred-thousand newly designed compounds appear and almost the same numbers of compounds are sold out. Thus the total number of compounds in stock has not changed substantially. Also, the number of natural compounds has been increasing gradually. On the other hand, the number of fragments has been increasing recently, since fragmentbased drug discovery became a trend in medicinal chemistry.
Fig. (6) shows one example of an SA prediction algorithm included in the MolDesk software package [17] (URL: http://www.moldesk.com/). This routine performs the SA prediction within about 0.1 seconds for a given compound with one click manipulation.
In the MolDesk software package, SA is calculated as follows: where c0, c1, c2, c3, and c4 are fitting parameters. Parameters c0-c4 are optimized to reproduce the SA determined by expert manual assessment. In this review, the SA determined by expert manual assessment is designated the "human SA" and the SA calculated by Eq. 1 is called the "calculated SA." SA is estimated from the probability of existence (Sprob) calculated based on a compound library, the number of symmetry atoms (Nsym), the total number of atoms (Ntot) of the compound, the number of chiral centers of the compound (Nchiral), and the graph complexity (Sgraphcomplexity) [25] . The Nsym is the number of chemically (topologically) equivalent atoms. If a compound consists of fragments frequently found in an available-compound database, it should be easy to synthesize. On the other hand, if a compound consists of fragments rarely or never found in an available-compound database, it would be difficult to synthesize. The probability of existence (Sprob) was calculated on the basis of the decomposition of the compound into fragments, and the probability of existence of each fragment was estimated according to the compound library. Any kind of substructure descriptor (the extended connectivity fingerprint (ECFP) descriptors developed by SciTegic [15] , MACCS key, Dragon, etc.) could be used for the SA prediction.
All compounds in the library were decomposed into small fragments. Let N and N(i) be the total number of fragments found in the library and the total number of fragments found in the library that were exactly the same as the i-th fragment of the compound in question, respectively. The probability of existence of the i-th fragment in library (P(i)) is given by
Eq. 3
The total probability of existence of the compound in question is then given as 10 10 .
Eq. 5
As shown in Fig. (7) , the compound library should consist of already-synthesized available compounds. (7) . Substructure-based synthetic accessibility (SA) prediction. SA is estimated from the probability of existence (Sprob) calculated based on a compound library, the number of symmetry atoms (Nsym), the total number of atoms (Ntot) of the compound, the number of chiral centers of the compound (Nchiral), and the graph complexity (Sgraph-complexity).
The correlation coefficients between the predicted SA values and the human SAs are about 0.5-0.8 for these prediction methods. The R value (0.56) and the average error (1.2) obtained by MolDesk are similar to those between the human SAs (R=0.59 with a standard deviation of 0.22 and average error=1.1).
CORRELATION AMONG HUMAN SAs
Takaoka et al. reported that the human SA values (synthetic accessibility (or synthetic easiness in the original text) values of visual inspection by individuals) were slightly dependent on the individual chemists, even within the same company. Nonetheless, while the concept of SA remains somewhat fuzzy and poorly defined in the manner of concepts like "good" or "bad," such abstractions are often quite useful. Tables 3-6 show the correlations among human SAs reported in previous articles [7, 10, 17] . The human SAs were strongly dependent on the skill and experience of the individual chemist. The SA values estimated by the 2 chemists who belonged to the same company were still similar to each other. The SA values estimated by the chemists from different companies were different from each other and showed almost no correlation. SA would be expected to depend on the equipment available at the individual company, as well as on the training and experience of the company chemists.
RELATIONSHIP BETWEEN THE SALES PRICE OF AP-PROVED DRUGS AND SA
In Japan, about 10% of approved drugs are not sold in the market, since the drug prices do not meet the drug development costs. Thus the drug price is an important factor in drug development. We examined the relationship between the sales price and SA of approved drugs in the United States and Japan (US) [17] . Of course, the price of a drug is critical to its practical adoption by patients. For this reason, the ability to predict the price of a new drug in the drug-design process would be highly useful.
The prices of new drugs in the United States and Japan showed a weak correlation to the calculated SA values. Their correlation coefficients were 0.32 and 0.29, respectively (see Fig. (8) ). The prices of generic drugs showed the same trends as the new drugs. The reason for this should be that the price of a generic drug follows the price of the original drug.
The price of a drug may depend on many kinds of costs, including the costs of development, phase trials, and patents, as described in the next section (see Fig. (9) ). In addition, the market size and efficacy of the drug should be considered to decide the price. This means that a drug that is difficult to synthesize is not always expensive. The average SA of a drug is about 6, meaning that the average difficulty of drug synthesis is not extremely high.
DRUG PRICES IN THE US AND JAPAN
Because different countries have different methods of setting the prices of drugs prices, these prices vary widely around the world. In the US, the pharmaceutical companies determine drug prices based on a capitalist paradigm. On the other hand, in Japan the government sets the price of drugs based on their estimated importance to the healthcare system. These differences also reflect the different health insurance systems in each country. Thus a comparison between the drug prices in the US and Japan should reveal differences between a free market-based and government-based healthcare system.
There is almost no correlation between the sales prices of drugs in the US and Japan [17] . On the other hand, Fig. (10) shows the correlation between the logarithm of the price of drugs in the US and the price in Japan. The correlation is very high (R = about 0.8). This means that the prices of drugs are roughly estimated and the values of drugs could change depending on each society.
CLOUD COMPUTING IN CADD
Cloud computing has become a quite popular technology. Usually, the cloud computer is a large-scale computer and computer resources such as CPU and disk space are served on demand (see Fig. (11) ). Two of the major cloud computer services are the Amazon Web Service (AWS: URL https://aws.amazon.com/?nc1=h_ls) and AZURE by Microsoft (URL: https://azure.microsoft.com/jajp/). The cloud computer is very similar to the conventional server computer. The difference between the cloud and conventional server is that the cloud is a virtual machine on which the OS, middleware, programs and computational environment must be prepared for application computing by users in general, and the virtual machine disappears when the users deallocates the virtual machine. Although this procedure (allocation and deallocation of the virtual machine) enables computers to be used flexibly, it is also complicated and time-consuming. The other important aspect of cloud computing is the requirement of high security or privacy. On a conventional server, we can see the status of other users' jobs. Conversely, we cannot see any information on the other users of a virtual machine. The scalability and high security have enabled many pharmaceutical companies to perform their virtual screenings, similarity searches and MD simulations on cloud computers.
Fig. (8).
Correlation between SA and the price of newly approved drugs in the US.
Fig. (9).
Setting of drug prices in the US and Japan. The setting of drug prices depends on the country, type of disease and type of drug.
Fig. (10).
Correlation between the sales prices of drugs in the US and Japan. Cloud computing also enables us to access specialized hardware. The general purpose graphics processing unit (GPU) computational resource is somewhat troublesome for many users. Since the evolution of the GPU hardware is very fast, the GPU software is strongly dependent on the hardware, and the CUDA software (URL: https://developer.nvidia.com/cuda-zone) depends on the GPU hardware. Every year, new GPU hardware has appeared and the CUDA version has been updated. The GPU program should be tuned up for each GPU, since the performance of GPU programs depends on the balance of the number of GPU cores and memoryband width. Also the application of GPU is quite limited. This means that the GPU is used only when the GPU programs are available. In contrast, CPUs are always used for all application programs.
One of the problems of cloud computing is that the cloud machine is a virtual machine that basically begins as an empty box in cases where we allocate our own resources. We must prepare our own computational environment before starting target computations such as virtual screenings or MD simulations. This is almost equivalent to the procedure of setting up a brand new machine, and it must be done each time a new connection is made to the cloud computer. The other problem is that we must pay for the number of computations and in many cases it is difficult to predict the computational cost before the computations have actually been run. Finally, it is necessary to retrieve the data from the cloud computer before the close of service on each use.
AWS provides more than 40 services (see Fig. (12) ), including CPU, disk, database, and security resources. Most of the charges for these services are proportional to the amount of usage of the cloud services. To realize a scientific calculation, the users must integrate and combine these cloud services adequately. Because there are so many cloud services, selecting the best combination for each scientific calculation can be hard work for the users. In addition, the users need resources on demand. Instead of asking the system providers, in some cases the users can manage their cloud computing using the available cloud services.
The cloud controller software assists in the process of preparing the computational environment and retrieval of data. There have been several reports on this software. Since the explanation of the mechanism of the cloud controller software is beyond the scope of this review, we will simply explain how to use such software. The controller software depends on the kind of computations to be made. Thus, we must select the best controller software for the computer programs that we want to use. AceCloud is a commandline cloud controller [26] . The users can submit their jobs, check the job status, abort them, and retrieve the results through AceCloud (see Fig. 13 ).
We show one example of the commercial cloud controller software "MolGate" (BY-HEX LLP, Tokyo Japan. URL http://byhex.com/ 2015) in Fig. (13) . MolGate is a web-based program with SSH communication and the users can use both the CPU and GPU resources. When input files are prepared for MD simulation a pri- ori, MolGate can prepare the environment on the cloud and start the calculation within 10 minutes. The example shows how to perform MD simulation on AWS. Fig. (13) shows the procedures followed by the user. The user must allocate and deallocate the computational resources manually in addition to performing the login process. The procedure consists of the following four steps.
Step Step 2. Users select the data that should be calculated on the local machine. MolGate prepares the computational environment for this calculation as a background job. The simulation programs, analysis programs and MPI environment are prepared on AWS automatically. Users select the data that should be calculated on the local machine. MolGate sends or unzips the zipped files.
Step 3. Users indicate the number of servers and estimate the CPU cost of the job. MolGate calculates the expected CPU time for the job. Users should change the server type and/or modify the input file for the simulation if necessary. Then users perform their job.
Step 4. Users retrieve the resulting data after the job is finished. On AWS, users can see only their virtual machine. Once the CPU resources are allocated, users will not be bothered by other users. Most of the costs of cloud computing are due to the CPU time, while the disk space usage is very inexpensive or even free in many cases.
To use the cloud computer, we should estimate the cost of the job a priori [27] . The computational cost depends on the size of the simulation system, the duration of the simulation, what kind of program will be used, and which service (type of server machine) of the cloud will be used. BY-HEX LLP provides a service for predicting the cost (URL: http://by-hex.com/). The total number of atoms is entered into the simulation system, and the site estimates the price per one MD simulation step. This prediction is still primitive, but the service is useful.
MACHINE SETUP: GPU AND COMPOUND DATABASE
GPU computation has also become very popular [28] [29] [30] [31] [32] [33] [34] [35] [36] . GPU computing is particularly suitable for performing molecular dynamics simulation programs like AMBER [33] , Gromacs [34] , NAMD [35] and psygene-G/myPresto [36] . The computational details of these programs are described in detail elsewhere. Some of these GPU programs are freely available. One of the most serious problems for end users is how to set up the GPU machine for these MD programs. The other problem is that the system size for the GPU computation must be larger than the minimum size that is determined by the program. Since most GPU programs adopt a spacedecomposition method for parallel computing, the system must be decomposed into sub systems. This means that the MD of a small system (like a single molecule) is not suitable for GPU computing. Fig. (14) shows how to set up the MD program for the GPU. Many computers have GPU boards that are used mainly for graphics. To utilize the GPU for an application program, we must uninstall the GPU graphics driver software and install CUDA, a computer language for use with GPU. Most of the GPU-MD programs adopt CUDA for GPU computations. The slot number of each GPU board in the computer must be explicitly indicated in CUDA. Suppose our machine has three GPU boards. In some cases, a poor GPU is allocated to slot 1 for graphics. The additional two expensive GPU boards have slots 0 and 2 for the MD simulation. In some cases, a poor GPU is allocated to slot 0 for graphics. The additional two expensive GPU boards have slots 1 and 2 for the Fig. (14) . Software and hardware GPU framework.
MD simulation. This allocation depends on the machine. If the GPU programs use a slow and a fast GPU board, the computation speed depends on the speed of the slow GPU board. This setup job is somewhat time-consuming work. The user can request that the computer vendor set up the machine, or in some cases, the vendor will provide a pre-installed machine such as MolSpace (LEVEL FIVE Co., Ltd. Tokyo; URL: http://www.level-five.jp/).
In this section, we explain how to start using the GPU computation, since the set up the environment for the GPU computation is a much more time-consuming and complex process than the conventional CPU. Most of the GPU programs run on the CUDA language. This means that the GPU of the Intel Core-i series is not suitable for GPU computing, since the GPU of core-i is not designed for CUDA. Many computers utilize the GPU card for graphics. To use the GPU card for a scientific calculation program, we must stop using the GPU for graphics and change the status of the GPU card for application only. Our example is designed for CUDA7.0 running on Linux x86_64 (RedHat6 (RHEL6) and CentOS6). The RPM package of CUDA for RHEL6/CentOS6 is available from the NVIDIA CUDA download website (https://developer.nvidia.com/cuda-downloads).
In order to use GPUs for running CUDA application programs, we must check the versions of the software and hardware. For example, CUDA for CentOS6 runs on the combination of kernel 2.6.32, GCC version 4.4.7, and GLIBC version 2.12. Each CUDA version runs on each GPU card. We must check what kind of GPU card is available on the CUDA GPUs site (https://developer.nvidia.com/cuda-gpus). These points can be checked using the following 5 steps.
Step 1. Check the version of the OS (obtained by "$ cat /etc/*release").
Step 2. Check the version of the kernel (obtained by "$ uname -a").
Step 3. Check the version of GCC (obtained by "$ gcc --version").
Step 4. Check the version of GLIBC (obtained by "$ rpm -q glibc").
Step 5. Check the GPU card (obtained by "$ lspci | grep -i nvidia").
In the present review, we explain how to set up the GPU for MD simulation mainly for an NVIDIA CUDA environment for RedHat6/CentOS6, since CUDA is now popular for GPU simulations. In order to use the NVIDIA driver PRM package, an EPEL package must be installed. This process should be done by following 7 steps as follows.
Step 1. Download a suitable EPEL, such as # yum install (http://dl.fedoraproject.org/pub/epel/epel-release-latest-6.noarch.rpm).
Step 2. Install the CUDA on the command mode (run level 3), then set the run level using the command "# /sbin/init 3."
Step 3. Install the CUDA repository ("# rpm --install cuda-reporhel6-7-0-local-7.0-28.x86_64.rpm").
Step 4. Clear the cache of yum ("# yum clean expire-cache").
Step 5. Install CUDA by yum ("# yum install cuda"). Answer yes ("y") to all the questions.
Step 6. Restart the computer system by typing the command "# /sbin/shutdown -r now."
Step 7. Change the default parameter of EPEL. Change "enable=1" to "enable=0" for [epel] in the file "/etc/yum.repos.d/epel.repo".
In order to compile our GPU application on our computer, we must set the path for the CUDA library. We add the following two lines in ~/.cshrc for c-shell or ~/.bashrc for bash. export PATH=/usr/local/cuda/bin:$PATH export LD_LIBRARY_PATH=/usr/local/cuda/lib64:$LD_LIBRARY_PA TH Before starting our own application calculations, we check the software and hardware environment.
We download the sample program for CUDA and compile it using the following two steps.
Step 1. Put the CUDA sample on an suitable directory. For example, to put the sample on the current directory (.), we use the command "$ cuda-install-samples-7.0.sh .".
Step 2. Compile the sample using the command ("$ cuda-installsamples-7.0.sh .").
In the above section, we have shown how to prepare the CUDA environment for GPU applications. Now we can start the GPU applications. There are several GPU programs available on the Internet, and most of these are MD simulation programs. We will explain how to use psygene-G of the myPresto program suit developed by our group, since most of the other application programs should follow a similar procedure. Psygene-G is available on the myPresto download site (http://presto.protein.osakau.ac.jp/myPresto4/); after downloading, unzip the file using any suitable directory.
Psygene-G is an MPI parallel GPU program [36] . To compile this program, we must modify Makefile for our software environment. There are two Makefiles. One is for the MPI parallel program part (src/Makefile) and the other is for the CUDA program part (src/cuda/Makefile). Users should modify the Makefile of each application program in a manner similar to the following example.
Modification of Makefile for the MPI program (src/Makefile) to GPU in this example: (1) The CUDA version is indicated as "CUDA=cuda.x.y" for CUDA version x.y. (2) Activate the "#GPU Lib settings" block. 
